Access Vascular is developing a suite of venous access devices that use our novel, patented biomaterial which is designed to prevent the most common and costly complications in venous access. Our first product, FDA-cleared HydroPICC, has demonstrated a 30x reduction in thrombosis versus a standard polyurethane catheter.* *Data on file at Access Vascular. Reduction of thrombosis accumulation was evaluated using in vitro and in vivo models.